Facebook-f Twitter Linkedin Youtube
SUBSCRIBE
Facebook-f Twitter Linkedin Youtube
SUBSCRIBE

Allergy & Immunology CE Activities

ALLERGY & iMMUNOLOGY blog

View Details

6 Ways to Personalize Your Patient’s Asthma Treatment Plan

Asthma management is increasingly becoming more personalized. Here are 6 ways you can help personalize treatment for your patients with asthma that is severe or difficult to control.
  • Allergy & Immunology, Pulmonology
  • Blog
DOWNLOAD
View Details

Try These Diets for Your Patients with EoE

In infancy, you can see feeding problems, and as the child progresses to adulthood, you will see them complain about vomiting, abdominal pain, difficulty swallowing, food impaction, and all of this may cause them to avoid eating certain foods, eat very slowly, or avoid social situations where food is involved.
  • Allergy & Immunology
  • Blog
DOWNLOAD

RMEI Presentations

LATEST ALLERGY & IMMUNOLOGY ARTICLES

RSS Latest Allergy & Immunology Articles
  • T-Cell Engager–Mediated HLA Antibody Depletion before Kidney Transplantation July 30, 2026
    A patient with high-level HLA sensitization received T-cell engager–mediated HLA antibody depletion with teclistamab, a bispecific B-cell maturation antigen–directed CD3 T-cell engager, which enabled kidney transplantation.
    Martina Schatzl, Katharina A. Mayer, Hermine Agis, Susanne Haindl, Daniela Kriks, Gottfried Fischer, Markus Exner, Gideon Hönger, Nikolina Veljancic, Daniela M. Allmer, Irene Graf, Matthias Diebold, Philip F. Halloran, Anne Halpin, Caishun Li, Lori West, Nicolas Kozakowski, Georg A. Böhmig
  • Platelet-Activating Anti–Platelet Factor 4 Disorders July 30, 2026
    This review summarizes platelet-activating anti–platelet factor 4 disorders, including heparin-induced thrombocytopenia and related syndromes, highlighting diagnosis, antibody mechanisms, and treatment strategies.
    Theodore E. Warkentin, Andreas Greinacher
  • Iptacopan in IgA Nephropathy — Final 24-Month Data July 30, 2026
    Alternative complement pathway overactivation contributes to IgA nephropathy. In a placebo-controlled trial, iptacopan, a complement factor B inhibitor, significantly slowed kidney-function decline in patients with IgA nephropathy.
    Jonathan Barratt, Necmi Eren, Naoki Kashihara, Bart Maes, Dana V. Rizk, Brad Rovin, Hernán Trimarchi, Hong Zhang, Weiming Wang, Ismail Kocyigit, Chuanming Hao, Vladimir Tesař, Kenan Turgutalp, Li Yang, Guangqun Xing, Valter Duro Garcia, Seung Hyeok Han, Wanhong Lu, Antonio Pisani, Julia Weinmann-Menke, Frank Eitner, Nicolas Guerard, Dmytro Butylin, Luca Monaco, Emil Scosyrev, Annabel Magirr, Ronny Renfurm, Thomas Hach, Vlado Perkovic, the APPLAUSE-IgAN Study Group*

RMEI LIGHTNING TALKS

View Details

4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we've learned so far

RMEI has released pairings of live and online programs approximately twice per year since 2016 grouped into “phases” which share clinical areas of focus and are based on findings from the previous phase of education. In total, 16 activities have launched to date with 4 activities currently live. The purpose of this analysis is to better understand the impact of multi-year iterative education on a clinical audience. Presented at: Society for Academic CME (SACME), virtual, February 2021; Accreditation Council for Continuing Medical Education (ACCME), virtual, April 2021.
  • Allergy & Immunology
  • 2021
View Details

Effectiveness of 5-year IBD Provider Online Educational Intervention Program

There is considerable practice variability among providers caring for inflammatory bowel disease (IBD) patients. Limited data exists on the effectiveness of educational interventions targeting IBD providers to address these gaps. We report outcomes for a 5-year provider education training program which culminated in an enduring online education resource and clinical decision support tool.
  • Gastroenterology
  • 2021

Previously Published CE Activities